Related Experiment Video
Updated: Mar 19, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Novel TLR7 gain-of-function variant and review of the associated disease spectrum
Maud Tusseau1,2,3, Claire Desvignes4, Guilaine Boursier3,5,6
1Inserm U1111, CNRS, UMR5308, ENS of Lyon, International Center of Infectiology Research, Claude Bernard University Lyon 1, Lyon, France.
Abstract:
Early-onset systemic lupus erythematosus (SLE) is frequently associated with a more severe phenotype and may be linked to monogenic causes in at least 10% of all juvenile SLE cases. Recent advances in immunogenetics have identified Mendelian variants linked to inborn errors of immunity, underlying SLE. Toll-like receptor 7 (TLR7), an endosomal RNA sensor, has emerged as a key contributor to lupus pathogenesis through aberrant activation. We report a novel P435S gain-of-function (GOF) variant in TLR7 identified in a female patient presenting with early-onset SLE, recurrent infection, and neuroinflammatory features. Functional assays demonstrated the gain-of-function effect, confirming its pathogenicity and supporting its role in disease onset and progression. To further define the clinical spectrum of TLR7 GOF-associated disease, we conducted a systematic review of 11 additional reported cases, highlighting shared and divergent phenotypic features. These findings expand the understanding of TLR7-mediated autoimmunity and underscore the importance of genetic screening in early-onset SLE with atypical features.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Principles of Pharmacogenetics: Types of Genetic Variants
Leaky Scanning
Translation
Translation Produces the Building Blocks of Life
Proteins are...
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

